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Abstract
Rationale Salvinorin A (SA) is a highly selective kappa
opioid receptor agonist and the putative psychoactive
compound in Salvia divinorum (SD), an increasingly
abused hallucinogenic plant.
Objectives The objectives of this study were to characterize
the physiological and subjective effects of SA versus
placebo and measure drug and metabolite levels.
Methods Sublingual SA doses up to 4 mg were administered
in dimethyl sulfoxide/polyethylene glycol 400 solution to
eight SD-experienced subjects using a placebo-controlled
ascending-dose design.
Results No dose of SA produced significantly greater
physiological or subjective effects than placebo. Further-
more, effects did not resemble reported “typical” effects of
smoked SD. SA was detectable in plasma and urine, but
was, in most cases, below the reliable limit of quantification
(0.5 ng/mL).
Conclusions Our results suggest that the sublingual bio-
availability of SA is low. Higher doses, alternate formula-
tions, or alternate routes of administration will be necessary
to study the effects of SA in humans.
Keywords Salvia divinorum . Salvinorin A . Kappa opioid
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Introduction
An estimated 1.8 million Americans have tried Salvia
divinorum (SD), a psychoactive mint that traditionally had
been used for divination and healing in the Mazatec region
of Mexico (Substance Abuse and Mental Health Services
Administration 2006). SD use is also occurring in Europe
(Pavarin 2006) and Japan (Tsujikawa et al. 2008), and SD is
sold in smoke shops and over the web in preparations with
often inaccurately labeled and varying strength (Wolowich
et al. 2006). The psychoactive agent in S. divinorum is
believed to be salvinorin A (SA), a trans-neoclerodane
diterpenoid (Ortega et al. 1982; Valdés et al. 1984). Siebert
reported that when administered to humans by vaporization
and inhalation, SA is psychoactive with effects substantial-
ly similar to those of the whole leaf (Siebert 1994). A recent
placebo-controlled trial confirmed this, reporting intense
self-rated and observer-rated effects from a smoked dose of
1 mg SA (Addy 2010). Several animal studies have also
confirmed the psychoactivity of SA (Butelman et al. 2004;
Carlezon et al. 2006; Fantegrossi et al. 2005; Valdés et al.
1987). SA is the first known naturally occurring selective
kappa opioid and may be the most potent naturally occurring
hallucinogen (Roth et al. 2002). Limited clinical studies
suggest kappa opioids induce effects, including dysphoria,
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hallucinations, and dissociation (Walsh et al. 2001).
Although reported effects of SD appear brief and range
from laughter to depersonalization (González et al. 2006), a
few reports raise the question of possibly persisting
neuropsychiatric effects (i.e. paranoia, psychosis) (Breton et
al. 2010; Paulzen and Grunder 2008; Przekop and Lee
2009). One case report of paranoia and cognitive impairment
sometimes attributed to SD appears to have been caused by
marijuana, illustrating the difficulties of defining psychoac-
tive effects without controlled trials (Singh 2007).
Anecdotal reports suggest that SD produces strong
effects when taken orally (Valdés 1983) or when held in
the mouth (Siebert 1994), but there have been conflicting
reports on sublingual absorption of pure SA. Psychoactivity
has been reported from sublingual doses as low as 100 μg
(Ott 1996), but in other reports, no consistent effects have
been seen at doses up to 2 mg (Siebert 1994) or even 12 mg
(Zhah 2009).
Most SA users smoke the drug (Baggott et al. 2010;
González et al. 2006); however, due to individual differ-
ences in smoking technique, peculiarities of smoking
apparatuses, and losses of drug to combustion, determin-
ing the delivered dose of a smoked drug can be difficult or
impossible. In addition, maximal psychoactive effects can
occur almost immediately after smoked drug delivery,
decreasing the ability to assess and document effects on
the ascending limb of the dose–response function. In
contrast to the typical smoked administration, which
produces rapid, brief, and intense effects, we sought to
produce effects that would be less intense, better con-
trolled, and more easily measurable (by virtue of their
increased duration: an estimated 45–60 min (Baggott et al.
2010). We therefore administered SA sublingually to
attain a slower onset (relative to smoking) and standardize
dose delivery. This study reports on the first laboratory-




An ascending-dose (0–4,000 μg SA, sublingual),
placebo-controlled design in eight SD-experienced sub-
jects was used. To be included, subjects had to be
between the ages of 21 and 45; healthy as determined by
medical history, mental status, and physical examina-
tions, laboratory tests of renal and hepatic function; and
have at least three self-reported SD experiences with and
no adverse reactions to SD or hallucinogen use. Subjects
were excluded for dependence on any illicit drug or
alcohol.
Sublingual doses ranged from 0 to 4,000 μg. This dose
range was selected based on a review of likely doses taken
recreationally (Ott 1995; 1996; Siebert 1994) and with the
goal of producing (at most) modest pharmacological effects
in humans. Dosing sessions were separated by at least 24 h.
The first two doses (placebo and 100 μg) were double-
blind; the remaining five doses (250, 500, 1,000, 2,000, and
4,000 μg) were single-blind. The predetermined stopping
criteria for dose escalation were a Visual Analog Scale
(VAS) “Intoxication” rating above 50%, a self-report
indication that the previous dose was not tolerable, or
clinically significant cardiovascular, neurological, or psy-
chiatric symptoms as determined by the study physician.
The study was approved by the California Pacific Medical
Center Institutional Review Board, and an Investigational
New Drug Exemption was obtained from the US Food and
Drug Administration.
Dose preparation
SA was isolated from dried commercial SD leaves
(Bouncing Bear Botanicals, Lawrence, KS) as previously
described (Munro and Rizzacasa 2003). Proton nuclear
magnetic resonance (300 MHz) and liquid chromatography
(LC)–mass spectrometry (MS) was consistent with past
results (Munro and Rizzacasa 2003) and showed no
detectable impurities. SA was soluble in 25% dimethyl
sulfoxide (DMSO)/75% polyethylene glycol 400 (PEG-400)
at 4,000 μg/mL and was stable for 6 days, as determined by
LC-MS/MS, with only trace amounts of the hydrolysis
product salvinorin B (SB) forming.
Doses were prepared by a research pharmacist. A
500-μg/mL SA solution was made in ethyl acetate;
appropriate doses were pipetted into scintillation vials, then
evaporated to dryness, and stored in a cool, dry location.
Doses were prepared by redissolving the SA in 1 mL of a
slightly viscous mixture of 25% DMSO/75% PEG-400;
both were USP grade (Coyerly et al. 1998).
Sublingual dosing procedure
SA in the DMSO/PEG-400 vehicle or the DMSO/PEG-400
placebo was administered sublingually with a needle-less
syringe. Subjects were instructed to hold the liquid without
swallowing for 5 min and were monitored for adherence.
After 5 min, subjects expectorated mouth contents into a
container for disposal then rinsed with 60 mL water before
swallowing.
Safety monitoring and outcome measures
Subjects were continually monitored for signs and symp-
toms of toxicity until 4 h post-dose. Heart rate, blood
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pressure, and oxygen (O2) saturation were measured with a
Philips C3 Patient Monitor and core temperature with an
ingested monitor (Minimitter Vitalsense) at baseline and
0.25, 0.5, 0.75, 1, 2, and 4 h post-dose. Plasma samples for
SA levels were obtained at 20 min, and all of the urine was
collected for the 4 h post-dose.
Assay for salvinorin A and B A sensitive and specific
liquid-chromatographic-atmospheric pressure chemical
ionization-tandem mass spectrometric (LC-APCI-MS/MS)
method was developed to measure SA and its primary
metabolite, SB, in human plasma and urine (see Appendix).
The C-4 trideuteromethyl ester analogs of the analytes
were utilized as the internal standards. The limits of
quantitation were 0.5 ng/mL for both SA and SB in plasma
and urine.
Visual Analog Scales Two VAS questionnaires, anchored
with “not at all” to “extremely,” were obtained. One
questionnaire (“any drug effect,” “good drug effect,” “bad
drug effect,” “high,” “stimulated,” “clear-headed,” “sedat-
ed,” “confused,” “drunken,” “insightful,” “closeness to
others,” and “intoxication”) was obtained at the same times
as physiological measures. The second questionnaire
(“Feelings of unreality,” “Difficulty controlling thoughts,”
“Size, depth, or shape of my surroundings seems changed,”
“My body or body parts seem changed,” “The passing of
time seems changed,” “Familiar things seem unfamiliar,”
“Some events, objects, or other people have new meanings
for me,” “Suspicious feelings that others might be against
me,” “When I close my eyes, I see complex abstract
patterns,” “When I close my eyes, I see objects or non-
living things,” “When I close my eyes, I see animals,
people, or beings,” and “When I close my eyes, I see places
or landscapes”) was obtained 2 h post-dose with subjects
answering for the time since dosing. During screening,
subjects were asked to rate their “typical” SA experience on
both VAS questionnaires.
The Subjective Drug Effects Questionnaire (SDEQ),
Altered States of Consciousness Questionnaire (APZ-OAV),
and Positive and Negative Affect Schedule (PANAS) were
administered between 2 and 4 h post-dose to broadly
characterize subjective symptoms typically altered by
hallucinogens. The SDEQ is a 272-item drug effects
questionnaire that was originally developed to distinguish
LSD from D-amphetamine and has subsequently been used
to characterize a variety of drug classes (Harris et al. 2002;
Katz et al. 1968; Snyder et al. 1968; Turek et al. 1974). The
APZ-OAV is a 94-item questionnaire widely used in
European studies of hallucinogen-like compounds (Dittrich
1998). The 20-item PANAS is widely used in psychological
and pharmacological studies to measure positive and
negative affect (Watson et al. 1988).
Results
Eight subjects (5 Caucasian men, 1 Caucasian woman, 1
Asian man, and 1 Asian woman) with an average age of
31 years (range, 21–45) received SA in this study. Subjects
reported a mean of 10 (range, 3–40) previous uses of SD
and reported experiencing “strong effects” an average of six
times (range, 2–20). One subject reported using SD in the
90 days before study entry, and two more reported using it
in the year before study entry. Therefore, tolerance to SA
among our subjects was unlikely. All subjects reported
abstinence from prescribed or recreational opiate agonists
for at least 90 days before study entry. Because no subject
met the stopping criteria, each subject was given all dose
levels of SA.
SA did not affect pulse, blood pressure, O2 saturation,
or core temperature. In general, no subjects reported
effects similar in quality or magnitude to their reported
“typical” SA exposures. There was no effect of dose on
responses to the SDEQ, APZ-OAV, PANAS, or most VAS
items. VAS scores for “headache” and “insightful” items
decreased relative to placebo, but effects were small and
inconsistent between doses. Only two male subjects
reported VAS “intoxication” scores above 25: both
occurred 15 min after the 1,000 μg dose. In contrast,
subject’s ratings of “typical” SA experiences using the
VAS (Fig. 1) and APZ-OAV measures were significantly
different from, and, in general, higher than, ratings for
both placebo and the 4,000 μg dose. Because of the low
intoxication ratings reported, we only assayed blood and
urine samples from the highest (4,000 μg) dose and the
two cases where intoxication scores were higher than 25.
Most SA concentrations were below the limit of quanti-
fication (Table 1).
Discussion
Sublingual doses of 4,000 μg SA did not produce even
mild effects. Scores on the VAS and APZ-OAV measures
indicated that the subjective experience of 4,000 μg failed
to differ significantly from placebo and was significantly
lower than scores for “typical” effects.
The lack of subjective effects and the low levels of SA in
blood and urine suggest that the sublingual bioavailability
of SA is poor. This is consistent with earlier anecdotal
reports that sublingual doses of up to 2 mg (Siebert 1994)
or 12 mg (Zhah 2009) produced no consistent effect, and
cast doubt on claims of detectable effects at doses as low as
100 μg (Ott 1995).
One possible factor in these discrepancies is the different
solvents used. We used 25% DMSO/PEG-400, while earlier
reports have employed ethanol (Siebert 1994), DMSO (Ott
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1995), or acetone (Ott 1995; Zhah 2009). SA may have
greater bioavailability in certain solvents. However, two
prior reports using acetone gave conflicting results, sug-
gesting that choice of vehicle does not fully account for the
discrepancy. DMSO, ethanol, and acetone are all irritants,
making controlled trials using these solvents difficult.
There are many reports of psychoactivity when SD is
taken by chewing the leaves or holding an infusion or
tincture in the mouth (Ott 1995; Siebert 1994). Similarly, in
early animal studies, crude SD extracts showed higher
potency than pure SA. However, no other active constituent
has been isolated from SD (Munro 2006), suggesting that
other compounds in SD may enhance the absorption of SA.
A similar effect occurs with the isoflavone daidzin, whose
bioavailability is enhanced tenfold in a crude plant extract
(Keung et al. 1996). Thus, future work might test SD
tinctures containing standardized levels of SA rather than
the pure compound.
Subject Age Gender Dose (μg) Plasma Urine
SA SB SA SB
3 30 M 1,000
4 24 M 1,000 0.665
1 24 M 4,000 0.484
2 39 M 4,000 – –
3 30 M 4,000 0.338 0.921 – –
4 24 M 4,000 1.214
5 21 M 4,000
6 45 M 4,000 0.52 0.295
7 24 F 4,000 0.119 0.57
8 40 F 4,000 0.672 0.874
Table 1 Urine and plasma
salvinorin levels (ng/mL)
Dash indicates not determined.






Suspicious feelings that others might be against me
Lethargy
Nervous
My body or body parts seem changed
Intoxication
When I close my eyes, I see animals, people, or beings
Closeness to others
When I close my eyes, I see places or landscapes
When I close my eyes, I see objects or non-living things
Familiar things seem unfamiliar
Confused
Difficulty controlling thoughts





The passing of time seems changed
Feelings of unreality
Size, depth, or shape of my surroundings seems changed
When I close my eyes, I see complex abstract patterns




Fig. 1 Four milligrams of salvinorin A had minimal subjective effects: each point indicates the mean VAS score for peak effects after 4 mg dose
(circle), peak effects after placebo (square), and “typical” experience (diamond)
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In conclusion, in this first controlled study of the effects
of SA in human subjects, sublingual doses up to 4,000 μg
in DMSO/PEG-400 were not psychoactive. These results
suggest that the sublingual bioavailability of pure SA is low
and that oral absorption of SA from SD depends on other
components of SD or the local effects of SD on conditions
in the mouth.
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Appendix
Method for determination of salvinorins A and B
in DMSO/PEG-400 by APCI LC/MS/MS
Sample preparation
Two solutions of salvinorin A were prepared at a concen-
tration of 4.00 mg/mL in DMSO–PEG-400 (25:75, v/v).
One was prepared and allowed to sit on the laboratory
benchtop at room temperature for 6 days, while the other
was prepared just before sample analysis. Just before
analysis, 100 μL of each solution was dissolved in
9.90 mL of ethyl acetate to provide two 10-mL solutions
at concentrations of 40 μg/mL.
Calibration standards were prepared by spiking mixtures
of salvinorin A and B in the following amounts in 16×
100 mm silanized screw-top culture tubes: 0, 10, 50, 100,
250, 500, 750, 1,000, and 2,000 ng/mL. Quality control
(QC) samples were prepared in duplicate at the following
concentrations: 50, 250, and 1,000 ng/mL. Each tube also
contained a mixture of the internal standards, salvinorin A
4-CO2CD3 and salvinorin B 4-CO2CD3, in the amount of
2,000 ng each.
Twenty-five microliters (1,000 μg) of the ethyl acetate
dilutions of the DMSO–PEG400 solutions were trans-
ferred to 16×100 mm silanized screw-top culture tubes,
which had been supplemented with 2,000 ng of each of
the internal standards. These samples were prepared in
duplicate.
Extraction and derivatization
To each tube was added 1 mL of water and 4 mL of an
ethyl acetate-heptane (1:3, v/v) mixture. The tubes were
vortex-mixed for 5 min and centrifuged at 3,000 rpm for
5 min. The aqueous layer was frozen in a dry ice–acetone
bath, the organic layer decanted into a clean, silanized tube,
and the solvent evaporated in the centrifugal evaporator. To
each tube was added 100 μL of a 5% (v/v) solution of acetic
anhydride-d6 in methylene chloride (CH2Cl2) and 100 μL
of 0.5% (w/v) N,N-dimethylaminopyridine in CH2Cl2. The
tubes were capped and vortex-mixed for 2 h, and the
reaction mixtures quenched by the addition of 1 mL of
methanol and vortex mixing for another 5 min. After
evaporation of the solvent the residue was partitioned
between 4 mL of an ethyl acetate-heptane (4:1, v/v) mixture
and 0.5 mL of 0.25 M sulfuric acid. Vortex-mixing for
5 min was followed by centrifuging for 5 min, freezing of
the aqueous layer, decanting of the organic layer into a
clean tube, and evaporation to dryness in the centrifugal
evaporator. The residues were reconstituted in 200 μL of
MeOH, filtered through 0.45 μm filters, and transferred
to 200 μL autosampler vial inserts. The inserts were
placed in vials, capped, and loaded onto the autosampler
tray.
Liquid chromatography
LC analyses were performed on a Thermo Separation
Products P4000 gradient pump. Separations were achieved
on a Phenomenex Synergi Polar (4.6×150 mm, 4 μm
particle size) reversed-phase HPLC column employing
0.1% formic acid and methanol as the mobile phase
components. The solvents were degassed before use,
employing a Thermo Separation Products SCM1000 vacu-
um degasser equipped with the optional helium sparging
module. The column was protected by the use of two
Phenomenex Security Guard cartridges installed in tandem
with the analytical column. The flow rate was 1 mL/min.
Analyses were carried out with a linear gradient of 0.1%
formic acid-methanol (50:50, v/v) to 100% methanol over a
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period of 15 min. All solvents were degassed before use by
sparging with helium.
Mass spectrometry
Mass spectrometric data was acquired with a Finnigan
TSQ7000 triple-stage-quadrupole instrument fitted with an
APCI API2 probe and interfaced with an APCI/ESI
controller unit. The vaporizer and heated capillary temper-
atures were maintained at 450°C and 150°C, respectively,
and the corona voltage was set at 4 kV. The nitrogen sheath
gas pressure was 60 psi; however, the auxiliary gas function
was not used. The low mass (0–2,000 amu) range was
selected. For recording data in the fullscan mode, the mass
spectrometer was scanned from 100 to 650 amu with a scan
time of 0.5 s. For MS/MS analyses, the argon gas pressure
in the collision cell was set to 2.6 mTorr. Quantitative
analyses were carried out in the selected reaction monitor-
ing mode, with the following transitions being monitored:
m/z 433 to m/z 373 for salvinorin A; m/z 436 to m/z 373 for
salvinorin B; m/z 436 to m/z 376 for salvinorin A-d3; and
m/z 439 to m/z 376 for salvinorin B-d3. The resolution was
set to 0.6 amu and the scan times to 0.25 s. The collision
energy for each transition was 15 V.
Prepared dose stability testing
Finnigan Xcalibur/LCQuan software was used to generate the
calibration curves (non-linear regression, 1/X weighting) and
calculate concentrations using peak-height ratios of analyte/
internal standard. Standard curves were generated from 0 to
2,000 ng/mL.
A concentration of salvinorin A in DMSO–PEG-400
(25:75, v/v) of 4.00 mg/mL should calculate to 1,000 ng/
mL. The following results were obtained:








The results of the analyses indicate a 1% difference
between the calculated values for the two sets of samples,
which is statistically insignificant. The analyses also
detected trace amounts of the hydrolysis product, salvinorin
B, in both samples.
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